Summary of Key Points Core Viewpoint The announcement details the interest payment schedule for the convertible bonds issued by Guangdong Jiayuan Technology Co., Ltd. for the year 2025, including the relevant dates and financial terms associated with the bonds. Group 1: Convertible Bond Details - The bond name is Guangdong Jiayuan Technology Co., Ltd. Convertible Bonds [5] - The total issuance amount is RMB 1.24 billion [5] - The bond has a six-year term from February 23, 2021, to February 22, 2027 [5] - The interest rates for the bond are structured as follows: 0.4% for the first year, 0.6% for the second year, 1.0% for the third year, 1.5% for the fourth year, 2.5% for the fifth year, and 3.0% for the sixth year [5][6] Group 2: Interest Payment Information - The interest payment record date is February 13, 2026, and the payment date is February 24, 2026 [2][7] - The interest for the fifth year (2025) is calculated at a rate of 2.5%, resulting in a payment of RMB 25 per bond (before tax) [6][9] - The actual payment after tax for individual investors will be RMB 20 per bond [9] Group 3: Taxation and Payment Process - Individual investors are subject to a 20% tax on interest income, leading to a net payment of RMB 2.00 per bond after tax [9] - The company has appointed China Securities Depository and Clearing Corporation Limited Shanghai Branch for bond payment and interest distribution [8] - Non-resident investors are exempt from corporate income tax on interest income from these bonds until December 31, 2027 [10] Group 4: Upcoming Shareholder Meeting - The first temporary shareholder meeting for 2026 is scheduled for February 27, 2026 [14] - The meeting will utilize both on-site and online voting methods [15][18] - The agenda includes the election of the new board of directors, with a cumulative voting system to be employed [33][34]

Core Viewpoint - The announcement details the administrative penalty imposed on Yuan Zhishuang, a director and vice president of Qingdao Dingshin Communication Co., Ltd., for engaging in short-term trading of the company's stock, which violates the Securities Law of the People's Republic of China [1][2][3]. Group 1: Administrative Penalty Details - Yuan Zhishuang sold a total of 610,000 shares of Dingshin Communication stock from November 25 to November 26, 2025, with a transaction amount of 4.8537 million yuan [3]. - On November 27, 2025, he bought back 200,000 shares for a total of 1.6120 million yuan, indicating a violation of the six-month rule for trading [3]. - The China Securities Regulatory Commission (CSRC) determined that Yuan's actions constituted a violation of Article 44 of the Securities Law, leading to a warning and a fine of 120,000 yuan [3]. Group 2: Company Impact - The administrative penalty is directed solely at Yuan Zhishuang and does not affect the company itself, ensuring that the company's daily operations will not be significantly impacted [4]. - The company plans to learn from this incident and will enhance the legal and regulatory training for its directors and senior management to prevent similar occurrences in the future [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002212 证券简称：天融信 公告编号：2026-002 天融信科技集团股份有限公司 第七届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、会议召开情况 天融信科技集团股份有限公司（以下简称"公司"）第七届董事会第三十次会议于2026年2月9日以通讯表 决方式召开，会议通知于2026年2月4日以直接送达、电子邮件等方式向全体董事发出，全体董事对会议 通知发出时间无异议。公司应出席会议董事9名，实际出席会议董事9名，会议由董事长李雪莹女士主 持，公司高级管理人员列席了本次会议。本次会议的召集和召开符合《中华人民共和国公司法》和《天 融信科技集团股份有限公司章程》的有关规定。 二、会议审议情况 （一）以9票同意，0票反对，0票弃权，审议并通过《关于公司为全资孙公司2026年度银行综合授信提 供担保总额度的议案》； 由于经营发展需要，董事会同意公司为全资孙公司北京天融信网络安全技术有限公司（以下简称"天融 信网络"）2026年度金额不超过人民币140,000.00万元的银行 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000703 证券简称：恒逸石化 公告编号：2026-023 恒逸石化股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示 1．本次股东会未出现新增、变更、否决议案的情形。 2．本次股东会未涉及变更前次股东会决议的情形。 恒逸石化股份有限公司（以下简称"公司"）于2026年2月9日采用现场与网络投票相结合的方式召开了 2026年第一次临时股东会（以下简称"本次股东会"），审议并通过了相关议案，现将有关事项公告如 下： 一、会议召开和出席情况 （一）召开时间 1．现场会议时间：2026年2月9日（星期一）下午14:30。 2．网络投票时间：2026年2月9日。其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2026年2月9日9:15一9:25、9:30－11:30、13:00－15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为：2026年2月9日9:15－2026年2月9日15:00。 （二）召开方式：现场表决与网络投票相结合的 ...

Group 1 - The core viewpoint of the announcements is the disclosure of the main operational data for the pig farming business of Fujian Aonong Biological Technology Group Co., Ltd. for January 2026, highlighting significant growth in sales and inventory [1][2]. - In January 2026, the company sold 166,600 pigs, representing a year-on-year increase of 35.36% and a month-on-month increase of 2.63% compared to December 2025 [1]. - The pig inventory as of January 2026 was 758,600 pigs, which is a 54.84% increase compared to January 2025 and a 2.05% increase from the end of December 2025 [2]. Group 2 - The company is actively promoting the optimization of pig farming capacity, adjusting farming layout, scale, and breed structure, while continuing to focus on cost reduction and resource concentration to develop advantageous capacity [2]. - The disclosed operational data is based on internal statistics and is unaudited, intended to provide investors with timely insights into the company's pig farming business [3]. Group 3 - The announcements also include information regarding the shareholding status of major shareholders, specifically that the major shareholder, Zhangzhou Aonong Investment Co., Ltd., and its concerted actors hold a total of 328,255,547 shares, accounting for 12.6108% of the total share capital [6]. - As of February 6, 2026, the planned share reduction by certain shareholders, including Wu Youcai and Guo Qinghui, was not executed during the designated period [6][8].

Meeting Overview - The first extraordinary general meeting of shareholders was held on February 9, 2026, at 14:30 [3] - The meeting combined on-site and online voting methods [6] - A total of 856 shareholders attended, representing 2,422,749,071 shares, which is 37.9374% of the total voting shares [8] Voting Results - The proposal to elect Mao Huiyu as a non-independent director was approved with 2,415,062,935 votes in favor, accounting for 99.6828% of the valid votes [12] - The meeting did not encounter any rejected proposals [1][2] Legal Compliance - The meeting's procedures and voting conformed to relevant laws and regulations, ensuring the validity of the resolutions [14]

Meeting Overview - The second extraordinary general meeting of shareholders was held on February 9, 2026, at the company's administrative building in Jiangyin, Jiangsu Province [2] - The meeting was convened by the board of directors and chaired by Mr. Yin Fuhua, utilizing a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [2][3] Attendance and Voting - All 9 current directors and the board secretary attended the meeting, along with other senior executives [4] - The meeting had no rejected resolutions, and the voting process was deemed legal and valid, with special resolutions requiring more than two-thirds of the votes from the attending shareholders [3][5] Resolutions Passed - The proposal to elect Mr. Wu Liangwei as an independent director of the sixth board of directors was approved [3] - The voting for this proposal included a separate count for minority investors [3]

Core Viewpoint - The major shareholder, Tianjin TEDA Investment Holding (Group) Co., Ltd., plans to reduce its stake in Tianjin TEDA Resource Recycling Group Co., Ltd. by up to 29,383,577 shares, representing no more than 2% of the total share capital after excluding shares in the repurchase account, within three months starting from 15 trading days after the announcement [2][4][6]. Group 1: Shareholder Information - The major shareholder, Tianjin TEDA Investment Holding (Group) Co., Ltd., holds 486,659,104 shares, accounting for 32.98% of the total share capital of the company [2]. - The shares to be reduced are sourced from the transfer from Tianjin TEDA Group Co., Ltd. to Tianjin TEDA Investment Holding [4]. Group 2: Reduction Plan Details - The reason for the planned reduction is based on the strategic arrangements of the major shareholder [3]. - The reduction will be executed through block trading [5]. - The specific reduction period is set for three months starting from 15 trading days after the announcement [6]. Group 3: Compliance and Commitments - The major shareholder has adhered to all previous commitments and has not violated any terms related to shareholding intentions [8]. - The planned reduction complies with relevant laws and regulations, ensuring that it will not lead to a change in control of the company or significantly impact its governance structure [10].

证券代码：603123 证券简称：翠微股份 公告编号：临2026-002 债券代码：188895 债券简称：21翠微01 北京翠微大厦股份有限公司 关于控股股东向公司全资子公司提供借款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、借款事项概述 （一）基本情况 翠微集团为公司控股股东，上述事项构成关联交易。根据《上海证券交易所股票上市规则》（2025年4 月修订）第 6.3.18 条规定，关联人向上市公司提供资金，利率水平不高于贷款市场报价利率，且上市公 司无需提供担保，上市公司可以免于按照关联交易的方式审议和披露。根据《公司章程》规定，本次事 项需提交董事会审议，无需提交股东会审议。 （三）董事会审议情况 2026年2月9日，公司召开第八届董事会第四次会议审议通过了《关于控股股东向公司全资子公司提供借 款的议案》，表决结果：同意 9票，反对 0 票，弃权 0 票。 二、关联方介绍 翠微集团是海淀区国资委所属国有独资有限责任公司，法定代表人匡振兴，注册资本472.328.9994万 元，住所：北京市海淀区复兴路33 ...

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of the injectable GenSci136 drug, which is intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1][2]. Group 1: Drug Information - The product name is injectable GenSci136, and it is a Class 1 biological product developed by Jinsai Pharmaceutical for the treatment of IgAN [1]. - The clinical trial application was approved under acceptance number CXSL2600033, allowing the drug to proceed with clinical trials [1]. Group 2: Disease Context - IgAN is the most common primary glomerulonephritis globally and accounts for 39.73% of primary glomerulonephritis cases in China, primarily affecting individuals aged 30 to 40 [2]. - The disease progresses slowly but has a poor prognosis, with 20%-50% of patients eventually progressing to renal failure, posing a significant burden on families and the healthcare system [2]. - There is a substantial unmet clinical need for effective treatments for IgAN, as existing therapies have limitations in efficacy and safety [2]. Group 3: Drug Mechanism and Potential - Injectable GenSci136 is designed as a B-cell maturation antigen (BCMA) trimeric fusion protein, which enhances the blocking activity against endogenous ligands, potentially impacting the survival and differentiation of B lymphocytes and plasma cells [3]. - The drug aims to provide a new, safe, and effective first-line targeted treatment option for IgAN patients, with the potential for long-term application without the need for preventive anti-infection treatment [3].